Last reviewed · How we verify
NCT03899922: UVETOX
Monitoring Drug-induced Uveitis
trial testing Drugs inducing uveitis in Uveitis in 1,000 participants. Completed in 4 April 2023.
1 April 2020
Quick facts
| Lead sponsor | Groupe Hospitalier Pitie-Salpetriere |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 April 2019 |
| Primary completion | 1 April 2020 |
| Estimated completion | 4 April 2023 |
| Sites | 1 location across France |
Drugs / interventions tested
- Drugs inducing uveitis — full drug profile →
Conditions studied
- Uveitis — all drugs for Uveitis →
- Uveitis Drug-Induced — all drugs for Uveitis Drug-Induced →
- Eye Diseases — all drugs for Eye Diseases →
- Uvea--Diseases — all drugs for Uvea--Diseases →
Sponsor
Groupe Hospitalier Pitie-Salpetriere
Who can join
18 and older, any sex, with Uveitis or Uveitis Drug-Induced. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Several drugs and chemotherapies seem to induce uveitis. This study investigates reports of uveitis, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03899922
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Uveitis
Currently open trials in the same condition.
- NCT07262437 — Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles · NA · active not recruiting
- NCT07176130 — Demographics and Clinical Characteristics of Ocular Inflammatory Diseases in Singapore · active not recruiting
- NCT06974162 — Metagenomics for Ocular Inflammation · recruiting
- NCT06431373 — A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis · Phase 3 · active not recruiting
- NCT06310837 — Effect of Immunosuppressants With Adalimumab Biosimilars vs Corticosteroids on Noninfectious Uveitis · NA · active not recruiting
Other Groupe Hospitalier Pitie-Salpetriere trials
Trials by the same sponsor.
- NCT06515678 — Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension · active not recruiting
- NCT05934214 — EXploring Immune-related Adverse Events of Immune checkpoinT Inhibitors Using VigiBase, the WHO Pharmacovigilance Databa · completed
- NCT05819736 — Pharmacokinetics Study Of Rivaroxaban and Apixaban in Cancer Patients · unknown
- NCT04320017 — Joint Use of Electrocardiogram and Transthoracic Echocardiography With Other Clinico-biological Parameters in an Observa · completed
- NCT04314817 — Adverse Events Related to Treatments Used Against Coronavirus Disease 2019 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03899922 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Groupe Hospitalier Pitie-Salpetriere
- Last refreshed: 5 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03899922.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing